Allscripts (MDRX) Tops Q2 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- Wall St slightly higher as SK Hynix's stellar debut limits losses in chip stocks
- Oil prices fall on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- S&P Downgrades Oracle To 'bbb-/A-3'; Outlook Stable
- The real reason Meta shares are surging has nothing to do with its new AI model
Allscripts Announces Second Quarter 2021 Results
August 5, 2021 4:14 PM EDTSecond quarter GAAP diluted EPS of $0.15; non-GAAP diluted EPS of $0.23, up 35% year-over-year Generated $69 million of cash flow from continuing operations and $51 million of free cash flow in the second quarter Increasing 2021 outlook for Adjusted EBITDA and free cash flow
CHICAGO--(BUSINESS WIRE)-- Allscripts Healthcare Solutions, Inc. (Nasdaq: MDRX) (Allscripts) announced its financial results for the three and six months ended June 30, 2021.
Bookings(1) were $180 million in the second quarter of 2021. This result compares with $164 million in the second quarter of 2020. Contract revenue... More
